Literature DB >> 10770534

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy.

P Tebas1, W G Powderly, S Claxton, D Marin, W Tantisiriwat, S L Teitelbaum, K E Yarasheski.   

Abstract

BACKGROUND: The use of highly active antiretroviral therapy (HAART) has been associated with multiple metabolic complications whose pathogenesis is poorly understood at the present time.
METHODS: We performed a cross-sectional analysis of whole-body, lumbar spine (L1-L4) and proximal femur bone mineral density in 112 male subjects (HIV-infected patients on HAART that included a protease inhibitor, HIV-infected patients not receiving a protease inhibitor and healthy seronegative adults) using dual energy x-ray absorptiometry.
RESULTS: Men receiving protease inhibitors had a higher incidence of osteopenia and osteoporosis according to World Health Organization definitions: relative risk = 2.19 (95% confidence interval 1.13-4.23) (P = 0.02). Subjects receiving protease inhibitors had greater central: appendicular adipose tissue ratios than the other two groups (P < 0.0001). There was no relationship between the central: appendicular fat ratio and the lumbar spine or proximal femur bone mineral density t- or z- scores, suggesting that osteoporosis and body fat redistribution are independent side effects of HAART.
CONCLUSIONS: Osteopenia and osteoporosis are unique metabolic complications associated with protease inhibitor-containing potent antiretroviral regimens, that appear to be independent of adipose tissue maldistribution.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770534      PMCID: PMC3170993          DOI: 10.1097/00002030-200003100-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  Update: trends in AIDS incidence -- United States, 1996.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-09-19       Impact factor: 17.586

Review 2.  Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway.

Authors:  K Brinkman; H J ter Hofstede; D M Burger; J A Smeitink; P P Koopmans
Journal:  AIDS       Date:  1998-10-01       Impact factor: 4.177

3.  Severe premature coronary artery disease with protease inhibitors.

Authors:  K Henry; H Melroe; J Huebsch; J Hermundson; C Levine; L Swensen; J Daley
Journal:  Lancet       Date:  1998-05-02       Impact factor: 79.321

4.  New-onset diabetes mellitus associated with use of protease inhibitor.

Authors:  J A Eastone; C F Decker
Journal:  Ann Intern Med       Date:  1997-11-15       Impact factor: 25.391

5.  Severe diabetes associated with protease inhibitor therapy.

Authors:  F Visnegarwala; K L Krause; D M Musher
Journal:  Ann Intern Med       Date:  1997-11-15       Impact factor: 25.391

6.  Bone mineral density in patients with human immunodeficiency virus infection.

Authors:  N I Paton; D C Macallan; G E Griffin; M Pazianas
Journal:  Calcif Tissue Int       Date:  1997-07       Impact factor: 4.333

7.  Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease.

Authors:  J A Kanis; P Delmas; P Burckhardt; C Cooper; D Torgerson
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

8.  Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting.

Authors:  S Grinspoon; C Corcoran; K Miller; B M Biller; H Askari; E Wang; J Hubbard; E J Anderson; N Basgoz; H M Heller; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  1997-05       Impact factor: 5.958

9.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

10.  "Buffalo hump" in men with HIV-1 infection.

Authors:  J C Lo; K Mulligan; V W Tai; H Algren; M Schambelan
Journal:  Lancet       Date:  1998-03-21       Impact factor: 79.321

View more
  133 in total

1.  Metabolic bone disease in human immunodeficiency virus-infected children.

Authors:  Stephen Arpadi; Mary Horlick; Elizabeth Shane
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

2.  Bone disease in HIV infection.

Authors:  Maristella Francesca Saccomanno; Adriana Ammassari
Journal:  Clin Cases Miner Bone Metab       Date:  2011-01

3.  Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women.

Authors:  E M Stein; M T Yin; D J McMahon; A Shu; C A Zhang; D C Ferris; I Colon; J F Dobkin; S M Hammer; E Shane
Journal:  Osteoporos Int       Date:  2010-06-29       Impact factor: 4.507

4.  Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats.

Authors:  Tatyana Vikulina; Xian Fan; Masayoshi Yamaguchi; Susanne Roser-Page; Majd Zayzafoon; David M Guidot; Ighovwerha Ofotokun; M Neale Weitzmann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

5.  Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.

Authors:  Philip M Grant; Douglas Kitch; Grace A McComsey; Camlin Tierney; Belinda Ha; Todd T Brown
Journal:  HIV Clin Trials       Date:  2015-04-15

6.  Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss.

Authors:  Iwen F Grigsby; Lan Pham; Louis M Mansky; Raj Gopalakrishnan; Ann E Carlson; Kim C Mansky
Journal:  Biochem Biophys Res Commun       Date:  2010-02-18       Impact factor: 3.575

7.  Changes in HIV and AIDS in the United States: Entering the Third Decade.

Authors:  Scott Kellerman; Elin Begley; Brian Boyett; Hollie Clark; Jeff Schulden
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

Review 8.  Gynecologic issues in the HIV-infected woman.

Authors:  Helen E Cejtin
Journal:  Infect Dis Clin North Am       Date:  2008-12       Impact factor: 5.982

9.  Bilateral sub-trochanteric femur fragility fractures in a patient on antiretroviral therapy: a case based discussion and review of literature.

Authors:  Rajesh K Rajnish; Pratik M Rathod; Sameer Aggarwal; Saurabh Agarwal; Prasoon Kumar
Journal:  Int J Burns Trauma       Date:  2020-08-15

10.  The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling.

Authors:  Michael W-H Wang; Shi Wei; Roberta Faccio; Sunao Takeshita; Pablo Tebas; William G Powderly; Steven L Teitelbaum; F Patrick Ross
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.